Bacteriostatic and bactericidal activities of eight fluoroquinolones against Mex-AB-OprM-overproducing clinical strains of Pseudomonas aeruginosa

Journal of Antimicrobial Chemotherapy

Volumn 55, Issue 4, 2005, Pages 518-522

  Dupont, Philippe ^a   Hocquet, Didier ^a   Jeannot, Katy ^a   Chavanet, Pascal ^b   Plésiat, Patrick ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b HÔPITAL DU BOCAGE   (France)

Author keywords

Efflux; Monte Carlo simulation; Resistance

Indexed keywords

CIPROFLOXACIN; DNA TOPOISOMERASE (ATP HYDROLYSING) B; GREPAFLOXACIN; LEVOFLOXACIN; MOXIFLOXACIN; NORFLOXACIN; OFLOXACIN; PEFLOXACIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TROVAFLOXACIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIOSTASIS; BACTERIUM ISOLATE; BACTERIUM MUTANT; CHEMOTHERAPY; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERANCE; GENE OVEREXPRESSION; GENE REPRESSION; GENE TARGETING; HUMAN; MEMBRANE TRANSPORT; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MONTE CARLO METHOD; NONHUMAN; PREDICTION; PROTEIN SYNTHESIS; PSEUDOMONAS AERUGINOSA; STRAIN DIFFERENCE;

ANTI-BACTERIAL AGENTS; BACTERIAL OUTER MEMBRANE PROTEINS; DRUG RESISTANCE, BACTERIAL; FLUOROQUINOLONES; GENE EXPRESSION; MEMBRANE TRANSPORT PROTEINS; MICROBIAL SENSITIVITY TESTS; MUTATION; PSEUDOMONAS AERUGINOSA;

EID: 17444369811     PISSN: 03057453     EISSN: None     Source Type: Journal    
DOI: 10.1093/jac/dki030     Document Type: Article

References (33)

1. Li, X. Z., Nikaido, H. & Poole, K. (1995). Role of MexA-MexB-OprM in antibiotic efflux in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 39, 1948-53.
2. Poole, K., Tetro, K., Zhao, Q. X. et al. (1996). Expression of the multidrug resistance operon mexA-mexB-oprM in Pseudomonas aeruginosa: mexR encodes a regulator of operon expression. Antimicrobial Agents and Chemotherapy 40, 2021-8.
3. Cao, L., Srikumar, R. & Poole, K. (2004). MexAB-OprM hyperexpression in NalC-type multidrug-resistant Pseudomonas aeruginosa: identification and characterization of the nalC gene encoding a repressor of PA3720-PA3719. Molecular Microbioliology 53, 1423-36.
4. Llanes, C., Hocquet, D., Vogne, C. et al. (2004). Clinical strains of Pseudomonas aeruginosa overproducing MexAB-OprM and MexXY efflux pumps simultaneously. Antimicrobial Agents and Chemotherapy 48, 1797-802.
5. Craig, W. A. & Ebert, S. C. (1994). Antimicrobial therapy in Pseudomonas aeruginosa infections. In Pseudomonas aeruginosa Infections and Treatment (Baltch, A. L. & Smith, R. P., Eds), pp. 441-517. Marcel Dekker, Inc., New York, NY, USA.
6. Ziha-Zarifi, I., Llanes, C., Köhler, T. et al. (1999). In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM. Antimicrobial Agents and Chemotherapy 43, 287-91.
7. Li, X. Z., Ma, D., Livermore, D. M. et al. (1994). Role of efflux pump(s) in intrinsic resistance of Pseudomonas aeruginosa active efflux as a contributing factor to β-lactam resistance. Antimicrobial Agents and Chemotherapy 38, 1742-52.
8. Hocquet, D., Bertrand, X., Köhler, T. et al. (2003). Genetic and phenotypic variations of a resistant Pseudomonas aeruginosa epidemic clone. Antimicrobial Agents and Chemotherapy 47, 1887-94.
9. Andrews, J. M. (2001). Determination of minimum inhibitory concentrations. Journal of Antimicrobial Chemotherapy 48, Suppl. S1, 5-16.
10. Birmingham, M. C., Guarino, R., Heller, A. et al. (1999). Ciprofloxacin concentrations in lung tissue following a single 400 mg intravenous dose. Journal of Antimicrobial Chemotherapy 43, Suppl. A, 43-8.
11. Forrest, A., Ballow, C. H., Nix, D. E. et al. (1993). Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrobial Agents and Chemotherapy 37, 1065-72.
12. Montgomery, M. J., Beringer, P. M., Aminimanizani, A. et al. (2001). Population pharmacokinetics and use of Monte Carlo simulation to evaluate currently recommended dosing regimens of ciprofloxacin in adult patients with cystic fibrosis. Antimicrobial Agents and Chemotherapy 45, 3468-73.
13. Shah, A., Lettieri, J., Kaiser, L. et al. (1994). Comparative pharmacokinetics and safety of ciprofloxacin 400 mg i.v. thrice daily versus 750 mg po twice daily. Journal of Antimicrobial Chemotherapy 33, 795-801.
14. Zelenitsky, S. A., Harding, G. K. M., Sun, S. et al. (2003). Treatment and outcome of Pseudomonas aeruginosa bacteraemia: an antibiotic pharmacodynamic analysis. Journal of Antimicrobial Chemotherapy 52, 668-74.
15. Chien, S. C., Rogge, M. C., Gisclon, L. G. et al. (1997). Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrobial Agents and Chemotherapy 41, 2256-60.
16. Chow, A. T., Fowler, C., Williams, R. R. et al. (2001). Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrobial Agents and Chemotherapy 45, 2122-5.
17. Furlanut, M., Brollo, L., Lugatti, E. et al. (2003). Pharmacokinetic aspects of levofloxacin 500 mg once daily during sequential intravenous/oral therapy in patients with lower respiratory tract infections. Journal of Antimicrobial Chemotherapy 51, 101-6.
18. Geerdes-Fenge, H. F., Wiedersich, A., Wagner, S. et al. (2000). Levofloxacin pharmacokinetics and serum bactericidal activities against five enterobacterial species. Antimicrobial Agents and Chemotherapy 44, 3478-80.
19. Lubasch, A., Keller, I., Borner, K. et al. (2000). Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrobial Agents and Chemotherapy 44, 2600-3.
20. Preston, S. L., Drusano, G. L., Berman, A. L. et al. (1998). Levofloxacin population pharmacokinetics and creation of a demographic model for prediction of individual drug clearance in patients with serious community-acquired infection. Antimicrobial Agents and Chemotherapy 42, 1098-104.
21. Levey, A. S., Bosch, J. P., Lewis, J. B. et al. (1999). A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Annals of Internal Medecine 130, 461-70.
22. Forrest, A., Nix, D. E., Ballow, C. H. et al. (1993). Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrobial Agents and Chemotherapy 37, 1073-81.
23. Preston, S. L., Drusano, G. L., Berman, A. L. et al. (1998). Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Journal of the American Medical Association 279 125-9.
24. Zhang, L., Li, X.-Z. & Poole, K. (2001). Fluoroquinolone susceptibilities of efflux-mediated multidrug-resistant Pseudomonas aeruginosa, Stenotrophomonas maltophilia and Burkholderia cepacia. Journal of Antimicrobial Chemotherapy 48, 549-52.
25. Andrews, J. M. (2004). BSAC standardized disc susceptibility testing method (version 3). Journal of Antimicrobial Chemotherapy 53, 713-28.
26. Akasaka, T., Tanaka, M., Yamaguchi, A. et al. (2001). Type II topoisomerase mutations in fluoroquinolone-resistant clinical strains of Pseudomonas aeruginosa isolated in 1998 and 1999: role of target enzyme in mechanism of fluoroquinolone resistance. Antimicrobial Agents and Chemotherapy 45, 2263-8.
27. Le Thomas, I., Couetdic, G., Clermont, O. et al. (2001). In vivo selection of a target/efflux double mutant of Pseudomonas aeruginosa by ciprofloxacin therapy. Journal of Antimicrobial Chemotherapy 48, 553-5.
28. Mouneimné, H., Robert, J., Jarlier, V. et al. (1999). Type II topoisomerase mutations in ciprofloxacin-resistant strains of Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 43, 62-6.
29. Lomovskaya, O., Lee, A., Hoshino, K. et al. (1999). Use of a genetic approach to evaluate the consequences of inhibition of efflux pumps in Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy 43, 1340-6.
30. Goldman, J. D., White, D. G. & Levy, S. B. (1996). Multiple antibiotic resistance (mar) locus protects Escherichia coli from rapid cell kiling by fluoroquinolones. Antimicrobial Agents and Chemotherapy 40, 1266-9.
31. Martin, R. G. & Rosner, J. L. (2002). Genomics of the marA/soxS/rob regulon of Escherichia coli: identification of directly activated promoters by application of molecular genetics and informatics to microarray data. Molecular Microbiology 44, 1611-24.
32. Wright, D. H., Brown, G. H., Peterson, M. L. et al. (2000). Application of fluoroquinolone pharmacodynamics. Journal of Antimicrobial Chemotherapy 46, 669-83.
33. Schentag, J. J., Meagher, A. K. & Forrest, A. (2003). Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Annals of Pharmacotherapy 37, 1478-88.